Charles River Laboratories International Inc. (CRL)
CRL trades on NYSE in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-27, https://www.sec.gov/Archives/edgar/data/1100682/000110068226000022/0001100682-26-000022-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-27.
Profile
| Field | Value |
|---|---|
| Ticker | CRL on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2000 |
| SEC CIK | 0001100682 |
| SEC industry code | Services-Commercial Physical & Biological Research |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.0B |
| Net income | -$144.3M |
| Operating income | $25.2M |
| Net margin | -3.6% |
| Operating margin | 0.6% |
| Revenue growth | -0.9% |
| Cash | $213.8M |
| Total assets | $7.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $200.4M cash; operating cash flow $155.6M a quarter. | Report 2026-09-26 |
| Shares outstanding | 47,917,467 (2026-10-24); 49,215,471 a year earlier; 51,296,804 three years earlier. | Cover page 2026-10-24 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $4K, sold $42.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-26 | $982.7M | $333.1M | $254.1M | $200.4M | $2.4B | $4.0B | 10-Q 2026-11-04 |
| Q2 2026 2026-06-27 | $1.0B | -$1.5M | $179.7M | $192.0M | $2.6B | $4.0B | 10-Q 2026-08-05 |
| Q1 2026 2026-03-28 | $995.8M | -$14.8M | $41.1M | $191.8M | $2.7B | $4.0B | 10-Q 2026-05-07 |
| Q4 2025 2025-12-27 | $994.2M | -$276.6M | $147.5M | $213.8M | $2.1B | $4.0B | 10-K 2026-02-18 |
| Q3 2025 2025-09-27 | $1.0B | $54.4M | $213.8M | $207.1M | $2.2B | $4.0B | 10-Q 2026-11-04 |
| Q2 2025 2025-06-28 | $1.0B | $52.3M | $204.6M | $182.8M | $2.3B | $4.0B | 10-Q 2026-08-05 |
| Q1 2025 2025-03-29 | $984.2M | $25.5M | $171.7M | $229.4M | $2.5B | $4.0B | 10-Q 2026-05-07 |
| Q4 2024 2024-12-28 | $1.0B | -$214.5M | $159.4M | $194.6M | $2.2B | $4.0B | 10-K 2026-02-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3ASR | S-3ASR | 2024-05-09 |
| Latest annual report | 10-K | 2026-02-18 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report FORM 8-K | 8-K | 2026-11-09 |
| Latest proxy | DEF 14A | 2026-03-31 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.1% |
| 1 month | +13.0% |
| 3 months | +20.2% |
| Year to date | +69.4% |
| 1 year | +99.7% |
| From 52-week high | -10.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| MEDP | Medpace Holdings Inc. | $648.20 | -0.88% | $18.1B |
| INCY | Incyte Corp. | $120.27 | -0.58% | $24.5B |
| IQV | IQVIA Holdings Inc. | $264.73 | -0.15% | $43.6B |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier